Cargando…

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many promises. Here, CD33 and CD123 expression on AML blasts was studied by flow cytometry in a cohort of 319 patients with detailed inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehninger, A, Kramer, M, Röllig, C, Thiede, C, Bornhäuser, M, von Bonin, M, Wermke, M, Feldmann, A, Bachmann, M, Ehninger, G, Oelschlägel, U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080210/ https://www.ncbi.nlm.nih.gov/pubmed/24927407 http://dx.doi.org/10.1038/bcj.2014.39

Ejemplares similares

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34(+)CD123(+) Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia
por: Schmidt, Johannes R., et al.
Publicado: (2018)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
por: Wobus, Manja, et al.
Publicado: (2015)

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
por: Aliperta, R, et al.
Publicado: (2015)

Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia
por: Alakel, Nael, et al.
Publicado: (2017)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
por: Oelschlaegel, U, et al.
Publicado: (2016)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
por: Schönefeldt, C, et al.
Publicado: (2013)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Karyotype complexity and prognosis in acute myeloid leukemia
por: Stölzel, F, et al.
Publicado: (2016)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG Mice
por: von Bonin, Malte, et al.
Publicado: (2013)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Lipidomic approach for stratification of acute myeloid leukemia patients
por: Stefanko, Adam, et al.
Publicado: (2017)

Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms
por: Ruhnke, Leo, et al.
Publicado: (2021)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

P528: CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?
por: Schadt, Jonas, et al.
Publicado: (2023)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

Targeting CD33 for acute myeloid leukemia therapy
por: Liu, Jingjing, et al.
Publicado: (2022)

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants
por: Stasik, S., et al.
Publicado: (2018)

The prevalence of extramedullary acute myeloid leukemia detected by (18)FDG-PET/CT: final results from the prospective PETAML trial
por: Stölzel, Friedrich, et al.
Publicado: (2020)

Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia
por: Kunadt, Desiree, et al.
Publicado: (2020)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic
por: Aref, Salah, et al.
Publicado: (2020)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33(+) Acute Myeloid Leukemia
por: Dutour, A., et al.
Publicado: (2012)

Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
por: El Khawanky, Nadia, et al.
Publicado: (2021)

Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia
por: Safaei, Akbar, et al.
Publicado: (2018)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
por: Pelosi, Elvira, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p9g9aqn74otgvogjh6joqv1vnh